Quintrio
Home

IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

QuidelOrtho Corporation Common Stock

QDEL

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.

Last trade $10.04
Day change -$0.17 (-1.67%)
Day range $9.97 – $10.87
Volume 894,964
Market cap $701M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$700.53M
Price / earnings
—
Price / book
0.39×
Price / sales
0.27×
EV / sales
1.34×
EV / EBITDA
8.82×

Profitability

Earnings per share
-$5.38
Return on assets
-6.39%
Return on equity
-20.61%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1.64×
Current ratio
1.36×
Quick ratio
0.75×
Cash ratio
0.16×

Cash flow

Price / cash flow
88.68×
Price / free cash flow
—
Free cash flow
-$117.9M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for QDEL, quarterly periods
Line itemQ3 FY2026 Sep 27, 2026Q2 FY2026 Jun 28, 2026Q1 FY2026 Mar 29, 2026Q4 FY2025 Dec 28, 2025Q3 FY2025 Sep 28, 2025Q2 FY2025 Jun 29, 2025Q1 FY2025 Mar 30, 2025Q4 FY2024 Dec 29, 2024
Revenue$618.9M$630.9M$619.8M$723.6M$699.9M$613.9M$692.8M$707.8M
Cost of revenue$329.3M$358M$356M$403.2M$364.3M$339M$349.5M$381.7M
Gross profit$289.6M$272.9M$263.8M$320.4M$335.6M$274.9M$343.3M$326.1M
Selling, general and administrative$182.7M$189.7M$199.3M$194.4M$186.9M$178M$187M$187.5M
Research and development$42.5M$48.7M$44.9M$45.8M$41.5M$45.7M$53.2M$47.3M
Total operating expenses$297.1M$294.7M$295.6M$386.7M$1.04B$455.6M$310.7M$426.5M
Operating income-$7.5M-$21.8M-$31.8M-$66.3M-$704.8M-$180.7M$32.6M-$100.4M
Interest expense-$55.4M-$54.7M-$51.1M-$51M-$46.1M-$40.5M-$40M-$40.6M
Income before taxes-$62.9M-$81.2M-$79.5M-$112.4M-$756.9M-$229.6M-$8.8M-$140.9M
Income taxes-$9.1M$11.7M$12.3M$18.3M-$23.9M$25.8M$3.9M$37.5M
Net income-$53.8M-$92.9M-$91.8M-$130.7M-$733M-$255.4M-$12.7M-$178.4M
Net income attributable to common shareholders-$53.8M-$92.9M-$91.8M-$130.7M-$733M-$255.4M-$12.7M-$178.4M
EBITDA$131.7M$101.4M$85.5M$75.2M$157.3M$108.5M$155.8M$124.5M
Basic earnings per share-$0.78-$1.36-$1.35-$1.92-$10.78-$3.77-$0.19-$2.64
Diluted earnings per share-$0.78-$1.36-$1.35-$1.92-$10.78-$3.77-$0.19-$2.64

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

QuidelOrtho (QDEL) Beats Q3 Earnings and Revenue Estimates

QuidelOrtho reported Q3 2026 earnings of $0.31 per share, beating consensus estimates of $0.18 by 72%, though revenues slightly missed expectations at $618.9M. Despite the earnings beat, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends. The stock has underperformed the market by 50.9% year-to-date, and the Medical-Products industry ranks in the bottom 35% of Zacks industries.

Zacks Investment Research

Reasons to Add QuidelOrtho Stock to Your Portfolio for Now

QuidelOrtho Corporation (QDEL) shows strong Q2 2026 results with 21% adjusted EBITDA growth and expanding margins, supported by a diversified product portfolio and $50 million cost-saving initiatives through 2027. However, weak respiratory demand and overdependence on this segment pose risks, with the company adopting a cautious outlook for the 2026-2027 respiratory season.

GlobeNewswire Inc.

Lateral Flow Assay Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035

The global lateral flow assay market is projected to grow from USD 10.84 billion in 2025 to USD 17.66 billion by 2035, with a 5.0% CAGR. Growth is driven by increased adoption of point-of-care testing, technological innovations including CRISPR-based assays, and the shift toward decentralized diagnostic models. Major players include Abbott, Roche, Siemens Healthineers, and Thermo Fisher Scientific, with infectious disease testing accounting for 72.2% of market share.

GlobeNewswire Inc.

Pregnancy Detection Kits Market Analysis Report 2026 - Competitive Landscape, Opportunities, and Forecasts, 2021-2025 & 2025-2031

The global pregnancy detection kits market is projected to grow from USD 1.91 billion in 2025 to USD 2.69 billion by 2031, with a CAGR of 5.87%. Growth is driven by technological advancements enabling earlier detection, rising infertility rates, and increasing adoption of digital integration and e-commerce distribution. However, the market faces challenges from accuracy concerns and user error risks that erode consumer trust.

The Motley Fool

Rice Hall James Buys QuidelOrtho Stock

Rice Hall James & Associates purchased 574,877 shares of QuidelOrtho in Q4, increasing its stake to 833,791 shares valued at $23.8 million (1.3% of fund assets). The investment reflects confidence in the diagnostic technology company despite its stock being down 43.4% over the past year, as value investors anticipate improved financial results from recent leadership changes and strategic adjustments.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.